Pioszak Augen A, Hay Debbie L
Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
School of Biological Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
Adv Pharmacol. 2020;88:115-141. doi: 10.1016/bs.apha.2020.01.001. Epub 2020 Jan 27.
Receptor activity-modifying proteins (RAMPs) are a family of three single span transmembrane proteins in humans that interact with many GPCRs and can modulate their function. RAMPs were discovered as key components of the calcitonin gene-related peptide and adrenomedullin receptors. They are required for transport of this class B GPCR, calcitonin receptor-like receptor (CLR), to the cell surface and determine its peptide ligand binding preferences. Soon thereafter RAMPs were shown to modulate the binding of calcitonin and amylin peptides to the related calcitonin receptor (CTR) and in the years since an ever-growing number of RAMP-interacting receptors have been identified including most if not all of the 15 class B GPCRs and several GPCRs from other families. Studies of CLR, CTR, and a handful of other GPCRs revealed that RAMPs are able to modulate various aspects of receptor function including trafficking, ligand binding, and signaling. Here, we review RAMP interactions and functions with an emphasis on class B receptors for which our understanding is most advanced. A key focus is to discuss recent evidence that RAMPs serve as endogenous allosteric modulators of CLR and CTR. We discuss structural studies of RAMP-CLR complexes and CTR and biochemical and pharmacological studies that collectively have significantly expanded our understanding of the mechanistic basis for RAMP modulation of these class B GPCRs. Last, we consider the implications of these findings for drug development targeting RAMP-CLR/CTR complexes.
受体活性修饰蛋白(RAMPs)是人类中的一个由三种单跨膜蛋白组成的家族,它们与许多G蛋白偶联受体(GPCRs)相互作用并能调节其功能。RAMPs最初是作为降钙素基因相关肽和肾上腺髓质素受体的关键组分被发现的。它们是这类B类GPCR(降钙素受体样受体,CLR)转运至细胞表面所必需的,并决定其肽配体结合偏好。此后不久,RAMPs被证明可调节降钙素和胰淀素肽与相关降钙素受体(CTR)的结合,并且从那以后,越来越多与RAMPs相互作用的受体被鉴定出来,包括15种B类GPCR中的大多数(如果不是全部的话)以及其他家族的几种GPCR。对CLR、CTR和其他一些GPCR的研究表明,RAMPs能够调节受体功能的各个方面,包括转运、配体结合和信号传导。在此,我们综述RAMPs的相互作用和功能,重点关注我们了解最为深入的B类受体。一个关键重点是讨论最近的证据,即RAMPs作为CLR和CTR的内源性变构调节剂。我们讨论了RAMP-CLR复合物和CTR的结构研究以及生化和药理学研究,这些研究共同显著扩展了我们对RAMPs调节这些B类GPCR机制基础的理解。最后,我们考虑这些发现对靶向RAMP-CLR/CTR复合物的药物开发的意义。